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The OPA systemProliferation analysis is one of the basic approaches to characterize various cell types. In conventional cell prolif-
eration assays, the same sample cannot be observed over time, nor can a speciﬁc group within a heterogeneous
population of cells, for example, cancerous cells, be analyzed separately. To overcome these limitations, we
established an optical labeling-based proliferation assay system with the Kaede protein, whose ﬂuorescence
can be irreversibly photoconverted from green to red by irradiation. After a single non-toxic photoconversion
event, the intensity of red ﬂuorescence in each cell is reduced by cell division. From this, we developed a simple
method to quantify cell proliferation by monitoring reduction of red ﬂuorescence over time. This study shows
that the optical labeling-based proliferation assay is a viable novel method to analyze cell proliferation, and
could enhance our understanding of mechanisms regulating cell proliferation machinery. We used this newly
established system to analyze the functions of secreted interleukin-6 (IL-6) in cancer cell proliferation, which
had not been fully characterized. Reduction in proliferation was observed following IL-6 knockdown. However,
after co-culturing with IL-6-expressing cells, the proliferation of Kaede-labeled IL-6-knockdown cells was
restored. These data indicate that in basal-like breast cancer cells, IL-6 exhibits a paracrine effect to positively
regulate cell proliferation. Our results thus demonstrate that cancer cells can secrete signaling molecules, such
as IL-6, to support the proliferation of other cancer cells.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
The cell proliferation machinery orchestrates events including DNA
replication, duplication of cellular components, disappearance of the
nuclear membrane, chromosome segregation, reconstruction of the
nuclear membrane and cytoplasmic division. Although a signiﬁcant
number of studies have identiﬁed various factors that regulate cell
proliferation, we still have much to learn about how these processes
are regulated, particularly in transformed cells.
Cancer cells are highly proliferative as a consequence of the up-
regulation of cell cycle activators [1,2], the activation of signaling path-
ways [1,3], mutations in genes controlling the cell cycle [1,4], genomic
ampliﬁcation [5], and epigenetic changes [6]. The majority of cancerst-irradiation; IL-6, interleukin-
ator of transcription 3; TheOPA
m
o, Sakyo-ku, Kyoto 606-8507,cells actively proliferate in culture, and cancer cell cultures are useful
models for the study of cell proliferation.
Breast cancer cells develop inmammarymicroenvironments, arising
from the mammary epithelium. However, molecular and cellular
characteristics, including proliferative ability, vary among breast cancer
cells [7,8]. Breast cancers are classiﬁed into subtypes according to
differences in the expression of various markers [9–11]. The existence
of various types of breast cancer originating from an identical cellular
background suggests that use of these cell lines can enable the study
of a variety of potential mechanisms used to activate the proliferation
machinery, without having to consider differences in cellular origin
and environmental stimuli.
Conventional methods of analyzing cell proliferation can be grouped
into three categories. The ﬁrst method is counting the number of cells.
Cells are harvested at speciﬁed time points, and proliferation is quanti-
ﬁed by counting the number of cells following trypan blue staining. An
alternative is to measure the activity of succinate–tetrazolium reduc-
tase, which is active in living cells and inactive in dead cells. The second
analytic method is incubating proliferating cells with thymidine
analogs, such as tritiated thymidine, bromodeoxyuridine (BrdU), and
ethynyldeoxyuridine. Cells that have proliferated are identiﬁed by the
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into the genome during S-phase. The third method is to detect prolifer-
ation markers by immunostaining. Cells are ﬁxed and stained with
speciﬁc antibodies that target, for instance, the cell proliferationmarker
Ki-67, the S-phase marker PCNA, or the M-phase marker phospho-
histone H3.
Although these conventional methods are widely used, they have a
number of limitations. The data obtained by these methods consist of
sample values harvested from different cultures for each time point
and are not a continuous observation of the same culture. These
methods are unsuitable for analyzing the proliferative ability of a
particular cell type or group of interest in a heterogeneous population.
While staining for proliferation markers can detect proliferating cells
in a speciﬁc group, these results are only snapshots of growth.
Therefore, a novelmethod complementary to these conventional prolif-
eration assays is sorely needed.
Extracellular signaling molecules can stimulate proliferation.
Interleukin-6 (IL-6) is a secreted protein encoded by the IL6 gene. IL-6
forms a heterocomplex with the IL-6 receptor and glycoprotein 130
on the cytoplasmic membrane, which activates the Janus kinase/signal
transduction and activator of transcription 3 (STAT3) intracellular
signaling pathway [12,13]. IL-6 secretion is high in basal-like breast
cancer, a cancer subtype that possesses high proliferative and metasta-
tic ability [14–16]. IL-6 secreted by cancer cells has been suggested to
have paracrine effects in this type of breast cancer. In terms of cell
proliferation, however, the involvement of IL-6 is controversial
(reviewed in [17]), as administration of IL-6 has been reported to
variously inhibit, enhance, or have no effect on cell proliferation [17].
Further study with novel techniques will provide a new insight into
the function of IL-6 in cancer cell proliferation.
This study describes the design of an optical labeling-based prolifer-
ation assay system (the OPA system) that utilizes a photoconvertible
ﬂuorescent protein. As the ﬂuorescence emission wavelengths of
photoconvertible proteins are changed by irradiation, we can therefore
label particular cells by irradiation (optical labeling) [18,19]. In biology
research, optical labeling is known as a technique that allows
researchers to trace the behavior of a single cell, as well as analyze the
dynamics of a group of cells, such as group migration, distribution,
and growth. Different from these approaches, the OPA system uses
optical labeling to quantify cell proliferation based on the reduction in
photoconverted ﬂuorescent protein molecules per cell following cyto-
plasmic division.
The Kaede protein is a photoconvertible ﬂuorescent protein whose
color irreversibly changes from green to red after irradiation with
short wavelength light [20]. In this study, we used the Kaede protein
in the OPA system. We detected reductions in the ﬂuorescence of
photoconverted Kaede by simply taking pictures and measuring its
intensity in living cells, thus successfully quantifying proliferation. The
OPA system enables us to perform observations of cell proliferation in
the same culture over time. Furthermore, we can analyze the prolifera-
tive ability of a speciﬁc group of cells in co-culture experiments by
labeling the group of interest with Kaede. This study shows that the
OPA system facilitates the understanding of the molecular mechanisms
of cell proliferation. Using the OPA system, we examined the effect
of IL-6 knockdown in breast cancer cell lines. We also analyzed the
proliferation of IL-6-knockdown cells in co-culture experiments with
IL-6-producing cells. Our results show the function of cancer-secreted
IL-6 in cancer cell proliferation.
2. Materials and methods
2.1. Cell culture
Basal-like breast cancer cell lines Hs578T and MDA-MB-231, and
luminal breast cancer cell line MCF-7 were obtained from the American
Type Culture Collection (Manassas, VA, USA). Hs578T and MDA-MB-231 cells were maintained with Dulbecco's Modiﬁed Eagle Medium
(DMEM) (Sigma, R8758, St. Louis, MO, USA) with 10% fetal bovine
serum (FBS). MCF-7 cells were cultured with RPMI-1640 (Sigma,
D5796) containing 10% FBS and 1 nM estradiol (Sigma, E2758).
Lenti-X 293T cells (Takara Bio, 632180, Otsu, Japan), used to produce
lentiviral particles, were maintained with DMEM containing 10% FBS.
To obtain Kaede-expressing cell lines and shRNA-expressing cells,
drug selection was performed. We used 10 μg/mL blasticidin for
Kaede-expressing cells, and 1 μg/mL puromycin for shRNA-expressing
cells.
To analyze proliferation using the OPA system, cells were cultured
with phenol red-free media to reduce the background ﬂuorescence:
i.e., phenol red-free DMEM (Wako, 044-32955, Osaka, Japan) with 10%
FBS for Hs578T and MDA-MB-231 cells, and phenol red-free RPMI-
1640 (Life Technologies, 11835-030, Carlsbad, CA, USA) with 10% FBS
and 1 nM estradiol for MCF-7 cells.
Mitomycin C (MMC)was used to pharmacologically inhibit prolifer-
ation. MMC was purchased from Wako (133-15931). Control groups
were treated with the vehicle, i.e., 10% ethanol in ethylene glycol.
Tomeasure the red intensity of the entirewell, we used amicroplate
reader, Spectra Max Gemini EM (Molecular Devices, Sunnyvale, CA,
USA). In 1 day prior to assay, 1 × 104 cells per well were plated in a
96-well plate. Red ﬂuorescence was excited with 544 nm light, and
detected as 590 nm light. Data were collected with Soft Max Pro 5
software (Molecular Devices). Values were normalized to the non-
photoconverted control.
2.2. Vector construction
To introduceKaede and shRNAexpression,we used lentiviral vectors.
For Kaede expression, we used pLenti 6.3 vector (Life Technologies,
V533-06), which has a CMV promoter. The Kaede gene was purchased
from Medical and Biological Laboratories (AM-V0011, Nagoya, Japan).
We added a synthesized nuclear localization signal (NLS)-FLAG
sequence to the 3′ region of the Kaede gene in order to construct a
Kaede-NLS-FLAG fusion gene. The Kaede-NLS-FLAG fusion gene was
inserted downstream of the CMV promoter of the pLenti 6.3 vector.
For shRNA-mediated gene silencing, we used a pLKO.1 vector
(Addgene, 8453), which expresses the inserted shRNA sequence by
human U6 promoter. The synthesized shRNA template was inserted
between the AgeI EcoRI sites of the pLKO.1 vector. The shGFP and
shBMI1 sequences have been described previously [21]. The shIL6
sequence used was validated by a previous study [15].
2.3. Immunostaining
Immunostaining was performed to detect Kaede, pSTAT3 and
STAT3 proteins, and cyclobutane pyrimidine dimers in ﬁxed cells. The
procedure has been described previously [21]. Cells were ﬁxed with 4%
paraformaldehyde for 15 min at room temperature. Permeabilization
was performed with 10 μg/mL proteinase K (Wako, 169-21041) in
phosphate-buffered saline (PBS) on ice for 2 min. Primary antibodies
used were mouse anti-FLAG M2 antibody (Sigma, F1804, 1/300
dilution), mouse anti-cyclobutane pyrimidine dimer antibody TDM-2
(Cosmo Bio, NMDND001, Tokyo, Japan, 1/1500 dilution), rabbit anti-
phospho-STAT3 Tyr705 (D3A7) (Cell Signaling technology, X9145,
Danvers, MA, USA, 1/100 dilution) and rabbit anti-STAT3 antibody
(D3Z2G) (Cell Signaling Technology, 12640, 1/300 dilution). To detect
primary antibody binding via ﬂuorescence microscopy, we used
secondary antibodies, goat anti-mouse IgG antibody conjugated to
Alexa Fluor 488 (Life Technologies, A11001, 1/1000 dilution), and
goat anti-rabbit IgG antibody conjugated to Alexa Fluor 546 (Life
Technologies, A11010, 1/1000 dilution). Counter staining was per-
formed with Hoechst 33342 (Dojindo, 346-07951, Kamimashiki,
Japan, 1/1000 dilution).
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To detect dead cells, we performed a TdT-mediated dUTP nick end
labeling (TUNEL) assay using an in situ cell death kit (Roche, 11 684
817 910, Mannheim, Germany). The TUNEL signal was enhanced
by goat anti-ﬂuorescein antibody conjugated to Alexa Fluor 488 (Life
Technologies, A11096, 1/500 dilution). We analyzed cells at 24 h post-
irradiation (hpi).
2.5. Imaging
To determinewhether Kaedemolecule localizes to the nuclei, and to
perform time-lapse imaging, a confocal platform, TCS SP8 (Leica, Tokyo,
Japan), was used to collectﬂuorescence and brightﬁeld images. Hoechst
33342 signal was excited by 405 nm light and detected with 410–
470 nm light, while Alexa Fluor 488 was excited by 488 nm light and
detected with 500–550 nm light. The excitation and detection wave-
lengths of Kaede-red were 561 nm and 570–700 nm, respectively. In
time-lapse analyses, 4 optical sections were collected at 2.5-μm
intervals and projected. Cell cultures were photoconverted, and
then placed on the microscope stage in a humid chamber. During
time-lapse analysis, the temperature and CO2 concentration were
maintained at 37 °C and 5%, respectively. Images were collected with
the BrightR mode of TCS SP8 with a HyD detector, a highly sensitive
detection system that has no detectable quenching effects on a
specimen.
In order to observe Kaede-red ﬂuorescence, the immunostaining
signals and the TUNEL signals, images were captured by an all-in-one
BZ-9000 microscope (Keyence, Osaka, Japan). The excitation wave-
lengths were 340–380 nm for blue ﬂuorescence, 450–490 nm for
green ﬂorescence and 525–555 nm for red ﬂuorescence. The detection
wavelengths were 435–490 nm for blue ﬂuorescence, 510–560 nm for
green ﬂorescence and 577–632 nm for red ﬂuorescence.
2.6. Kaede photoconversion and quantiﬁcation of proliferation
For analysis of proliferation using the OPA system, 5 × 104 cells per
well were plated in a 24-well plate in 1 day prior to photoconversion.
We used polystyrene 24-well plate (BD Bioscience, 353047, San Diego,
CA, USA) for all-in-one microscope, and glass bottom dish (Matsunami
glass, D141400, Osaka, Japan) for confocal imaging. To change the
Kaede ﬂuorescence color, cultures were placed on the all-in-onemicro-
scope stage and exposed to the excitation light for blue ﬂuorescence,
which irradiated the culture from underneath through a 10× objective
lens, for 15 min at room temperature. The numerical aperture of the
10× objective lens used is 0.45. It has aberration correction, and is UV
transmissive.
To quantify the red intensity, images were captured immediately
after photoconversion, and at day 1, day 2, day 3, and day 4 post-
photoconversion. All pictures for quantiﬁcation were taken with a
1/2.5 s exposure for the green signal, and with a 1 s exposure for the
red signal with a 10× objective lens. In order to avoid analyzing
saturated signals, we checked against the saturation indicator of the
microscope system we used. Pictures were taken at the same position
in the same culture at each time point. Cell number in each picture
was counted manually. Fluorescence intensity was measured using
ImageJ software. We outlined each nucleus manually, and measured
its mean ﬂuorescent intensity. We randomly measured 50 cells and
calculated the mean red intensity in each picture. The relative red
intensity was calculated by dividing the mean value of each point by
the mean value immediately after photoconversion.
2.7. Immunoblotting
To analyze p53 protein level, we performed immunoblotting with
rabbit anti-p53 antibody (N-terminal) (Epitomics, 1005-1, Burlingame,CA, USA, 1/500 dilution). Rather than using secondary antibody to probe
for primary antibody binding, the Easy-Western-II detection system
(Beacle, BCL-EZS21, Kyoto, Japan) was employed. For an internal
control, we used mouse anti-β-actin antibody (Abcam, ab6276,
Cambridge, UK, 1/5000 dilution), and goat anti-mouse IgG antibody
conjugated to a peroxidase (Pierce biotechnology, 31340, Rockford, IL,
USA, 1/50,000 dilution). The chemical luminescence reagent used
was ECL Select (GE Healthcare, Buckinghamshire, UK). Signals were
detected by Ez-Capture II (ATTO, Tokyo, Japan) with ImageSaver5
software (ATTO).2.8. Quantiﬁcation of mRNA level
Procedures for total RNA extraction and cDNA synthesis have been
described previously [22], as have the protocols for quantitative reverse
transcription polymerase chain reaction (RT-PCR), data analysis, and
primer sequences [21]. In brief, 1 μg of total RNA was reverse tran-
scribed with SuperScript III (Life Technologies). Quantitative RT-PCR
was performed with FastStart Universal SYBR Green Master (Roche,
Mannheim, Germany). Ampliﬁcation of EF1A1 was used as an internal
control. The relativemRNA level and standard deviationwere calculated
according to instructions provided by Applied Biosystems.2.9. BrdU labeling
To label proliferated cells with BrdU, we cultured cells with 5 μM
BrdU for 1 or 2 days. BrdU labeling, permeabilization and DNaseI
treatment were performed using a BrdU Flow kit (BD Bioscience,
559619). BrdU detection was performed with an anti-BrdU mouse
monoclonal antibody (clone MoBU-1) conjugated to Alexa Fluor 647
(Life Technologies, B35133, 1/100 dilution).2.10. Flow cytometry
To analyze the ﬂuorescence of a group of cells, we performed ﬂow
cytometry. The Kaede-red signal and anti-BrdU antibody signal were
detected with the FL2 and FL4 channels of the FACS Aria II (BD
Bioscience), respectively. Ten thousand cells were run for each sample.
Acquired data were analyzed with FlowJo software (Tomy Digital
Biology, Tokyo, Japan).2.11. Enzyme-linked immunosorbent assay
To analyze the IL-6 levels in the supernatant, we performed enzyme-
linked immunosorbent assay (ELISA) with a Quantikine ELISA Human
IL-6 Immunoassay (R and D Systems, Minneapolis, MN, USA). In order
to prepare supernatant samples, we removed the culture medium,
added 300 μL of fresh medium, and incubated for 24 h in a 24-well
culture plate. The supernatant was then sampled. Cell number was
counted manually after supernatant sampling, and used to adjust the
volume of supernatant sample to 1 × 105 cells. We used 50 μL of
adjusted supernatant. ELISA for IL-6 was performed according to the
manufacturer's instructions.2.12. Statistics
The relative cell numbers, relative red intensities, and results from
quantitative RT-PCR and ELISA were analyzed with Student's t-test.
Fisher's exact test was used in order to analyze the results of the
TUNEL assay. P b 0.05 was considered statistically signiﬁcant. Error
bars in all graphs indicate standard deviations.
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3.1. Introducing the expression of the photoconvertible ﬂuorescent protein
Kaede into breast cancer cell lines
Newly synthesized Kaede molecules have green ﬂuorescence (sup-
plementary Fig. S1). Irradiation with ultraviolet or short wavelength
light irreversibly converts the ﬂuorescence from green to red. The red
photoconverted form of Kaede (Kaede-red) is not generated spontane-
ously under normal cell culture conditions. When a cell divides, cellular
components, including Kaede-red, are distributed into the two daugh-
ter cells. In this manner, the quantity of Kaede-red molecules per cell
is reduced after every division (Fig. 1A). Given that the ﬂuorescence in-
tensity of a cell reﬂects the amount of the ﬂuorescent protein present, a
reduction in Kaede-red intensity indicates that a cell has divided. This
allows quantiﬁcation of cell proliferation by comparing the red ﬂuores-
cence intensity at a particular analysis point with the intensity immedi-
ately after photoconversion (relative red intensity). Thismethod simply
requires taking pictures and measuring the red intensities. As sampling
from the culture is not required, proliferation can be observed over timeFig. 1. Design of the optical labeling-based proliferation assay system (the OPA system). (A
340–380 nm light generates Kaede-red molecules (magenta dots). When cells having Kaede-re
crease in the red intensity of each cell. In the OPA system, cells with high proliferative ability
(B) The Kaede expression constructs. Expression of Kaede-NLS-FLAG is under the control of t
Hs578T cells using an anti-FLAG antibody. The unlabeled control (C) and Kaede-labeled cells (
while C″ and D″ show themerged images. (E) Photoconversion of Kaede. A culture of cells is pl
room temperature. (F,G) Kaede ﬂuorescence detected by the green (F,G) and red (F′,G′) ﬁlter s
ﬂuorescence decreased (G), and red ﬂuorescence appeared (G′). Bars indicate 100 μm.in the same culture dish. This method also allows analysis of the prolif-
erative ability of a speciﬁc group of cells in a heterogeneous population
by labeling the speciﬁc group with Kaede, for example, in a co-culture
assay with non-labeled cells. In this study, we aimed to establish the
OPA system using the photoconvertible ﬂuorescent protein, Kaede.
To introduce Kaede expression into cell lines, we constructed a
vector consisting of the CMV promoter and the Kaede gene with an
NLS and a FLAG tag (Fig. 1B). The Kaede-NLS-FLAG molecule (hereafter
referred to simply as Kaede) localizes to the nucleus. This nuclear Kaede
signal enables easy identiﬁcation of each cell, even under conditions of
high cell density. The nuclear signal is distinct in living cells and is
distinguishable from the autoﬂuorescence of dead cells. This allows
us to measure the Kaede-red intensity, focusing on living cells. We
introduced the construct into three breast cancer cell lines, Hs578T,
MDA-MB-231, and MCF-7 cells, and obtained stable clones. Hs578T
and MDA-MB-231 cells are classiﬁed as basal-like breast cancers, and
have high proliferative ability. MCF-7 cells are luminal breast cancer
cells. MCF-7 cells exhibit strong cell-to-cell adhesion under laboratory
conditions, and possess lower proliferative ability than Hs578T and
MDA-MB-231 cells. To conﬁrm that the synthesized Kaede localizes to) Schematic of the OPA system with Kaede. Irradiation of Kaede-expressing cells with
d divide, Kaede-red molecules are distributed between the daughter cells, leading to a de-
have weak red intensity, while low or non-proliferative cells have stronger ﬂuorescence.
he CMV promoter. (C,D) Representative confocal images of immunostaining for Kaede in
D) are shown (n= 3 rounds of staining). C′ and D′ show Hoechst 33342 nuclear staining,
aced on themicroscope stage, and cells are irradiated with 340–380 nm light for 15 min at
ets. Red ﬂuorescence is not observed prior to irradiation (F′). After photoconversion, green
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tag of Kaede (Fig. 1C,D; supplementary Fig. S2). Confocal imaging
demonstrated that the FLAG signals overlapped with the Hoechst
signals, indicating that Kaede was in the nucleus. The FLAG signal was
not detected in uninfected control cells.
The color of Kaede ﬂuorescence shifts to red by irradiationwith short
wavelength light. In this study, we used a wavelength of 340–380 nm, a
light for blue ﬂuorescence excitation. To change the color of Kaede, a
culture was set on a ﬂuorescence microscope stage and exposed to
light at 340–380 nm for 15 min at room temperature (Fig. 1E). Prior to
irradiation, green ﬂuorescence, but not red ﬂuorescence, was observed
(Fig. 1F), indicating that Kaede-red is not generated under standard
cell culture conditions. Green ﬂuorescence was reduced by exposure
to 340–380 nm wavelengths, and red ﬂuorescence became detectable
(Fig. 1G). Therefore, this Kaede expression system evidently enables
the labeling of cells with Kaede-red by irradiation with 340–380 nm
light.
3.2. No detectable cellular damage following the Kaede photoconversion
procedure
To analyze proliferation using the OPA system, photoconversion is
required. While ultraviolet irradiation is an effective way to change
the color of Kaede ﬂuorescence [20,23], exposure of cells to strong ultra-
violet light can lead to cellular damage and the initiation of a stress
response [24–26], both of which can affect cell growth. Therefore,
photoconversion conditions whereby no cellular damage or stress
occurs are required. Accordingly, this study photoconverted Kaede by
irradiation with 340–380 nm light, which is milder than irradiation
from an ultraviolet lamp.
We analyzed whether our photoconversion conditions caused
cellular damage. To examine the effect of photoconversion on cell
growth, pictures were taken in the same position immediately after
photoconversion (day 0), and up to day 4 post-irradiation. Cells were
counted, and the numbers relative to the number of cells at day 0 in
each culture were analyzed. Relative cell numbers of cultures exposed
to 340–380 nm light did not change signiﬁcantly at any time point
relative to the unirradiated control (Fig. 2A,B). We next analyzed cell
death via TUNEL assay. Cells were irradiated with 340–380 nm light,
incubated for 24 h, and TUNEL-positive cells was identiﬁed (Fig. 2C,D).
Exposure to light from an ultraviolet lamp for 2 min was used as a
positive control for cellular damage (Fig. 2E). The peak wavelength of
light from the ultraviolet lamp used is 257.3 nm,which is stronger ultra-
violet light than 340–380 nm. The ratio of TUNEL-positive cells did not
signiﬁcantly differ between cultures irradiated with 340–380 nm light
and the negative control (Fig. 2F; supplementary Table S1). These
results indicate that under these photoconversion conditions, cell
proliferation and survival are unaffected.
At the molecular level, ultraviolet light irradiation generates dimers
between two adjacent pyrimidine residues in nucleotide strands,
referred to as cyclobutane pyrimidine dimers [27].We used an antibody
speciﬁc for the cyclobutane pyrimidine dimer to detect their presence
[28]. No positive staining was observed in either the negative control
or the photoconverted cells (Fig. 2G,H), unlike in cells exposed to ultra-
violet light (Fig. 2I). In response to cellular stress, such as irradiation
with ultraviolet light, the p53 protein is stabilized and the transcription
of p53-regulated genes is altered [24,29]. We analyzed whether our
photoconversion conditions cause p53 stabilization and change the
expression of CDKN1A, a p53-regulated gene. Due to the p53 mutation
in cell lines Hs578T and MDA-MB-231, we used MCF-7 cells, which
have an intact p53 gene. We detected an increase in p53 protein levels
in the cells exposed to ultraviolet light at 12 hpi, compared with the
negative control. As our photoconversion conditions are milder than
ultraviolet irradiation, we also analyzed the cells at 6 and 12 hpi. In con-
trast to ultraviolet irradiation, no change in p53 level was observed
under these photoconversion conditions at either 6 or 12 hpi (Fig. 2J).CDKN1A transcription is positively regulated by p53. We performed
quantitative RT-PCR analysis for CDKN1A. Themean value of the control
receiving no irradiation was deﬁned as 1. No up-regulation of CDKN1A
expression was observed in cells exposed under our photoconversion
conditions, whereas a 5-fold increase in expression was seen following
ultraviolet irradiation (Fig. 2K). Nodetectable changes in the cyclobutane
pyrimidine dimer signal, the p53 protein level and the CDKN1A tran-
scription level indicate that irradiation with 340–380 nm light for
15 min does not cause cellular stress at the molecular level. Therefore,
these speciﬁc irradiation conditions can be used to convert the ﬂuores-
cence of Kaede without risk of cellular or molecular damage.
3.3. Reduction in Kaede-red intensity by cell division
The amount of Kaede-red per cell reduces every after cell division. To
observe the reduction in red intensity, time-lapse imaging was per-
formed beginning immediately after photoconversion (Supplementary
Movie). The reduction patterns of the red intensity were similar in
almost all actively proliferating cells and the red intensity of the whole
group changed homogeneously, indicating that the OPA system with
Kaede is suitable for analyzing the proliferation of a group of cells. To
examine the behavior of each cell in detail, we analyzed the movie
frame-by-frame, and traced each cell. Fig. 3A shows a representative
cell division event. In this ﬁgure, the cell initiated division at the time
point 2 h:20 min. Kaede-red dispersed into the cytoplasm at 3:20,
suggesting that the nuclear membrane had dissolved. The cell divided
at 4:00. Nuclear membranes were re-formed and Kaede-red once
again localized to the nuclei at 5:00.
To quantify changes in red intensity, we measured the mean inten-
sity of each nucleus. This measurement would not be valid, however,
if the nucleus size varied among cells. Reassuringly, the size of nucleus
did not markedly differ in each of the breast cancer cell lines examined,
i.e., Hs578T, MDA-MB-231, and MCF-7 cells (supplementary Table S2).
Therefore we used the mean intensity of each nucleus in the following
analyses. Although ﬂuorescence is quenched by time-lapse microscopy,
we did not observe a reduction in ﬂuorescence after 30 (5 h) or
60 (10 h) observations in cells that did not divide during analysis
(Fig. 3B).
If a cellular component is distributed equally between the two
daughter cells, the red intensity would theoretically be halved after
cell division. We measured the red intensities before a cell underwent
cell division and after the re-formation of the nuclear membrane in
thedaughter cells. Relative valueswere calculated by dividing the inten-
sity after a division by the intensity before a division. Although the value
did not consistently halve every division, the mean relative values over
50 divisions (100 daughter cells) were approximately half their original
intensities in Hs578T, MDA-MB-231, and MCF-7 cells (Fig. 3C; supple-
mentary Table S3). We analyzed the distribution of Kaede-red intensity
in the population of photoconverted cells by ﬂow cytometry, and
observed that the intensity was tightly distributed (supplementary
Fig. S3). These results imply that the red intensity of a given cell is
reduced each time that it divides, and that proliferation can be quanti-
ﬁed by calculating the mean relative value of a group of cells.
To analyze whether the red ﬂuorescence is retained if a cell is not
proliferating, we used MMC, a chemical that inhibits cell proliferation.
MMC treatment indeed inhibited cell proliferation in this study (supple-
mentary Fig. S4A). To analyze proliferation using the OPA system, we
measured the red ﬂuorescence at day 0 and day 3, and the relative red
intensity between these time points was calculated (Fig. 3D). Given
that the relative values would be inaccurate if saturated images were
used, we checked the images using the saturation indicator of the
microscope to ensure that only unsaturated signals were analyzed.
Compared with the red ﬂuorescence at day 0, the ﬂuorescence was
decreased at day 3 in the control cultures (Fig. 3E), but not in the
MMC-treated group (Fig. 3F), indicating that low or non-proliferating
cells retain high red intensity. These results afﬁrm that the proliferative
Fig. 2.No detectable cellular or molecular damages and no stress response following photoconversion. (A,B) The proliferation of Hs578T (A, n=4) andMBA-MB-231 cells (B, n=4) after
irradiation with 340–380 nm light and unirradiated control cells were analyzed. Pictures of the cultures were taken daily at the same position. The number of cells was counted, and the
relative value was calculated based on an adjusted cell number at day 0 set at 100. No statistically signiﬁcant changes were observed between the unirradiated control cells and cells that
were irradiatedwith 340–380 nm light at any time points examined. (C,D,E,F) Cell deathwas analyzed using a TUNEL assay. Representative images of unirradiatedHs578T cells (C, n=3),
cells irradiatedwith 340–380 nm light (D, n=3), and cells exposed to ultraviolet irradiation (E, n=5) are shown. Hoechst 33342was used as a counterstain (C′,D′,E′). The percentage of
TUNEL-positive cells was calculated by dividing the number of TUNEL-positive cells by the number of cells stained by Hoechst (F, supplementary Table S1). (G,H,I) DNA damage in
irradiated Hs578T cells was evaluated by immunostaining for cyclobutane pyrimidine dimers (n = 3). No detectable signal was observed in the negative control (G) or following
irradiation with 340–380 nm light (H). DNA damage was only observed after ultraviolet irradiation (I). Hoechst 33342 staining was used to identify the nucleus (G′,H′,I′).
(J) Immunoblotting demonstrates that increases in p53 levelswere detected only in samples irradiatedwith ultraviolet light (n=3). Anti-β-actin antibodywas used as an internal control.
(K) The relative mRNA level of CDKN1Awas analyzed (n = 3). In comparison with the unirradiated control, CDKN1A expression increased signiﬁcantly in ultraviolet-irradiated cells.
Student's t-test was used in A, B, and K. Fisher's exact test was used in F. n.s.: non-signiﬁcant change, **: P b 0.01. Error bars represent the standard deviation. Bars indicate 100 μm.
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cells move actively. As the OPA system analyzes the mean relative
value of a group of photoconverted cells, it can evaluate proliferation if
some cells migrate out of or enter the frame.
The change in red intensity at day 3 relative to day 0 reﬂected
change in cell number (Fig. 3D). We also analyzed the change in red
intensity relative to the value of total Kaede intensity (green + red)
(supplementary Fig. S4B), ﬁnding that the total Kaede intensity of
the MMC-treated group decreased, even though the cell number and
relative red intensity were unchanged compared with day 0 (supple-
mentary Fig. S4A; Fig. 3D). This discrepancy appears to be due to thechange in total Kaede intensity (supplementary Fig. S4C). An increase
in total Kaede intensity was observed in MMC-treated cells at day 3
compared with day 0. In proliferating cells, newly synthesized green
Kaede is reduced by cell division. However, in non-proliferating cells,
such as MMC-treated cells, newly synthesized green Kaede accumu-
lates, resulting in an increase in the total Kaede ﬂuorescence of non-
proliferating cells, as well as a difference in the total Kaede intensity
between proliferating and non-proliferating cells. These results indicate
that using red intensity relative to day 0, rather than to total Kaede
intensity, is simpler and more suitable for evaluating changes in
proliferation.
Fig. 3. Reduction in Kaede-red intensity by cell division. (A) A representative series of images of dividingMDA-MB-231 cells with Kaede-red ﬂuorescence is shown. Arrowheads indicate
the same cell. White and yellow arrowheads indicate the parent and daughter cells, respectively. (B) No signiﬁcant change in red intensity was observed in non-dividing cells (n= 30).
(C) Change in Kaede-red intensity was quantiﬁed by analyzing the relative values calculated by dividing the intensity of Kaede-red after cell division by the intensity of Kaede-red before
cell division (n= 50 divisions, supplementary Table S3). (D,E,F) Relative red intensities are shown (D). Images show the Kaede-red signal in the control MDA-MB-231 cells (E) and in
MDA-MB-231 cells treatedwith 0.5 μg/mLMMC (F). Student's t-test was used to analyze signiﬁcance.MMC:mitomycin C. Error bars represent the standard deviation. n.s.: non-signiﬁcant
change, **: P b 0.01. Bars indicate 50 μm in A and 100 μm in E and F.
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OPA system with Kaede
To quantify cell proliferation and to perform a time course analysis,
Kaede-expressing cells were cultured and photoconverted. Pictures
were taken immediately after photoconversion, and at day 1, day 2,
day 3, and day 4 post-irradiation (Fig. 4A). Cells were treated with
MMC or the vehicle after photoconversion to test whether the OPA
system could quantify changes in proliferative ability.
In the OPA system, proliferating cells have low Kaede-red intensity.
To show this, we analyzed changes in the relative cell number and the
relative red intensity, whichwere calculated by dividing their respective
value at a particular analysis point by the time point immediately afterphotoconversion. The relative cell number of the Hs578T cell control
increased from day 1 to day 4 (Fig. 4B), with the corresponding relative
red intensity of the same culture declining eachday (Fig. 4C). As expected,
the mean red intensity halved when the mean cell number doubled
(Fig. 4B,C at day 2, control). In addition, the mean red intensity became
one third of the original day 0 value when the mean cell number
increased by 300% (Fig. 4B,C at day 3, control). Together, these data
indicate that a reduction in the mean red intensity of the group reﬂects
the degree of cell proliferation. On the other hand, cultures treatedwith
1 μg/mL MMC did not grow (Fig. 4B) and the red intensity did not
remarkably decrease (Fig. 4C), indicating that inhibiting proliferation
causes retention of the red ﬂuorescence intensity. Similar patterns
of increasing relative cell number and decreasing red intensity were
Fig. 4. Quantiﬁcation of the effects of pharmacological and genetic inhibitions of proliferation via the OPA system. (A) Pictures were taken after cultures were irradiated to generate
Kaede-red at day 0. To observe the change in proliferation daily, images were taken at the same position at day 1, 2, 3, and 4 after irradiation. (B,C,D,E,F,G) Proliferation of Hs578T
(B,C, 1 μg/mL MMC, n = 4), MDA-MB-231 (D,E, 0.5 μg/mL MMC, n = 4), and MCF-7 (F,G, 1 μg/mL MMC, n = 4) cells. The relative cell number (B,D,F) and the relative red intensity
(C,E,G) are shown. (H,I) Proliferation of MDA-MB-231 cells following BMI1 knockdown is shown (n= 4), as indicated by the relative cell number (H) and the relative red intensity (I).
Student's t-testwas used to analyze the signiﬁcance between the experimental and control groups at each time point. n.s.: non-signiﬁcant change, *: P b 0.05, **: P b 0.01.MMC:mitomycin
C. Error bars represent the standard deviation.
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cells (Fig. 4F,G). As treatment with 1 μg/mL MMC over 4 days was
toxic to MDA-MB-231 cells, 0.5 μg/mL MMC was used in these cultures
instead. The mean red intensity did not decrease in MDA-MB-231 cells
when cell proliferation was inhibited with MMC (Fig. 4E). In MCF-7
cells, a signiﬁcant effect of MMC was observed at day 3 and day 4
(Fig. 4F,G). The red intensity did not decrease from day 3 to day 4
(day 3 vs. day 4, P = 0.14), during which the cell number did notincrease. This result indicates that MCF-7 cells are not sensitive to
1 μg/mL of MMC compared with basal-like breast cancer cells.
In addition to pharmacological inhibition of cell proliferation, we
performed genetic inhibition in MDA-MB-231 cells. We used shRNA-
mediated gene silencing for the BMI1 gene, which encodes a polycomb
protein. BMI1 epigenetically suppresses cyclin-dependent kinase
inhibitor genes. Therefore BMI1 knockdown leads to the expression of
cyclin-dependent kinase inhibitors, resulting in the inhibition of cell
35J. Itou et al. / Biochimica et Biophysica Acta 1853 (2015) 27–40proliferation. Indeed, MDA-MB-231 cells with BMI1 knockdown
exhibited inhibition of cell proliferation (Fig. 4H) and no reduction in
red intensity (Fig. 4I). High Kaede-red intensity was maintained in
non-proliferating BMI1-knockdown cells, suggesting that Kaede-red is
stable enough for use in the proliferation assays lasting 4 days. To
further analyze the stability of Kaede-red,wemeasured the red intensity
of the entire well (supplementary Fig. S5). We observed no change in
red intensity over 4 days in the control or MMC-treated cells, although
a slight reduction in red intensity was observed in MMC-treated
Hs578T and MDA-MB-231 cells at day 4 via the OPA system. Together,
these results conﬁrm that the OPA system can allow the evaluation of
differences in proliferative ability in genetic studies, as well as in
pharmacological studies.
Comparison of the OPA system with a conventional method for
analyzing cell proliferation (in this case, BrdU incorporation) could
help to highlight the advantages of the OPA system. Kaede-expressing
cells were photoconverted and treated with 5 μM BrdU. After a 1-
(Fig. 5A) or 2-day (Fig. 5B) incubation, the change in red intensity was
analyzed, as was the population of BrdU-positive cells. In Hs578T
cultures, the number of cells increased from day 1 to day 2 (Fig. 5C),Fig. 5. Comparison of the OPA system with BrdU labeling. (A,B) BrdU labeling and the OPA sy
(C,D,E,F,G,H,I,J,K) Cell number relative to day 0 (C,F,I), the population of BrdU-positive cells (D
(D,G,J, n= 4), and MCF-7 cells (E,H,K, n= 4) are shown. Error bars represent the standard deas did the number of BrdU-positive cells (Fig. 5D). In addition, the rela-
tive Kaede-red intensity decreased, also indicative of cell proliferation
(Fig. 5E). A similar pattern was observed in MDA-MB-231 (Fig. 5F,G,H)
and MCF-7 cells (Fig. 5I,J,K). In high proliferative cancer cells, the
number of BrdU negative cells was small at day 2 (supplementary
Fig. S6), indicating that almost all cells were proliferating. However
BrdU negative population was observed in a low proliferative cell line
at day 2 (supplementary Fig. S6), suggesting that there are slow or
non-proliferating cells.
While BrdU-positivity is also indicative of cell proliferation, an
increase in the number of BrdU-positive cells implies that the number
of proliferating cells increased. BrdU labeling cannot quantitatively
show howmany times the cells have proliferated, nor it analyzes prolif-
eration over time because BrdU detection requires sampling cells. In the
OPA system, the reduced red intensity indicates that cells have prolifer-
ated, with the mean relative red intensity of a group demonstrating the
degree of proliferation. Although both BrdU labeling and the OPA
system demonstrate that proliferation has occurred, only the OPA
system allows analysis of the degree of proliferation over time, as
shown in Fig. 4.stem were performed for the same culture. Cells were incubated for 1 (A) or 2 days (B).
,G,J), and red intensity relative to day 0 (E,H,K) in Hs578T (C,D,E, n= 4), MDA-MB-231
viation.
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IL-6 is a secreted protein that acts as a ligand to activate STAT3 [12,
13]. Activated STAT3 positively regulates cell growth. However, the
role of IL-6 signaling in breast cancer proliferation, as reviewed by
Dethlefsen et al., is still controversial [17]. Previous studies have been
done using conventional methods for analyzing cell proliferation. To
examine IL-6 function in this context, we analyzed cell proliferation
using the OPA system following IL-6 knockdown, allowing the analysis
of the proliferation of living cells over time within the same sample.Fig. 6. Inhibition of proliferation by IL-6 knockdown in basal-like breast cancer but not in lum
cells, as measured by ELISA (n= 3). (B) IL-6 knockdown reduced the level of IL-6 secreted by
cells. (F,G,H) The effect of shIL6 in MDA-MB-231 cells. (C,F) Graphs show the relative red in
(D,G) and shIL6-expressing cells (E,H) are shown. (I) Graph shows the effect of shIL6 in MCF-7
(n = 4). Student's t-test was used to analyze signiﬁcant differences between the experim
**: P b 0.01. Error bars represent the standard deviation. Bars indicate 100 μm.High IL-6 secretion has been observed in basal-like breast cancer cell
lines [14–16]. Consistent with previous studies, we detected high IL-6
levels in the supernatant of basal-like breast cancer cell cultures, such
as Hs578T and MDA-MB-231 cells, but not in luminal breast cancer
cells, such as the MCF-7 cell line (Fig. 6A). To analyze the effect of IL-6
on cell proliferation, an shRNA-mediated IL-6-knockdown system was
employed. IL-6 secretion by shIL6-expressing cells was less than half
of the shGFP-control (Fig. 6B). Knockdown of IL-6 elicited a signiﬁcant
reduction in the proliferation of basal-like breast cancer cells,
i.e., Hs578T (Fig. 6C,D,E) andMDA-MB-231 cells (Fig. 6F,G,H), indicating
that IL-6 positively regulates cell proliferation. Although the secretedinal breast cancer. (A) Endogenous IL-6 secretion by Hs578T, MDA-MB-231, and MCF-7
Hs578T cells (n= 3). shGFP was used as a control. (C,D,E) The effect of shIL6 in Hs578T
tensity in shIL6-expressing cells (n = 4). Representative pictures of the shGFP control
cells (n= 4). (J) Administration of IL-6 had no effect on the proliferation of MCF-7 cells
ental and control groups at each time point. n.s.: non-signiﬁcant change, *: P b 0.05,
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similar effects were observed after the IL-6 knockdown (Fig. 6C,F),
suggesting differences in IL-6 dependency.
On the other hand, the proliferation ofMCF-7 cellswas unaffected by
IL-6 knockdown (Fig. 6I). Further, addition of recombinant human IL-6
did not alter the proliferation ofMCF-7 cells (Fig. 6J). Our results suggest
that IL-6 is involved in the cell proliferation of basal-like breast cancer
cells, but not luminal breast cancer cells.
3.6. The paracrine effect of IL-6 on cell proliferation in basal-like breast
cancer
It is possible that cancer cell-secreted IL-6 promotes the proliferation
of other cancer cells (known as a paracrine effect). To evaluate whether
IL-6 exhibits a paracrine effect in basal-like breast cancer cells, we used
the OPA system in co-culture experiments with Hs578T and MDA-MB-
231 cells, the proliferative abilities of both of which were reduced by
IL-6 knockdown (Fig. 6C,F). The OPA system enables us to analyze the
proliferative ability of a speciﬁc group of cells within a heterogeneous
population (Fig. 7A). Thus, we co-cultured Kaede-expressing cells
with unlabeled cells. Kaede-red was generated by photoconversion
and cell proliferation was analyzed by measuring the red intensity.
We introduced shGFP (control) or shIL6 into Kaede-expressing cells
and unlabeled cells. Compared with the co-culture of unlabeled shGFP
cells with Kaede-labeled shGFP cells (shGFP + shGFP-Kaede), the
shIL6+ shGFP-Kaede showed no signiﬁcant difference in the prolifera-
tion of the subset of Kaede-labeled cells (Fig. 7B,C). This result indicatesFig. 7. Positive regulation of cell proliferation by secreted IL-6 in basal-like breast cancer cells. (
with non-labeled cells. The culture was then photoconverted, and the proliferation of Kaede-la
co-culture experiments (Hs578T cells). (B,C) The relative red intensities of shGFP- and shIL6
co-cultured with unlabeled shGFP- or shIL6-expressing cells. (D,E) Graphs show the effect of
(E, n = 4). Student's t-test was used to analyze signiﬁcant differences between the experim
**: P b 0.01. Error bars represent the standard deviation.that IL-6 knockdown does not affect the proliferation of other adjacent
cells. After co-culturing with shGFP cells, Kaede-labeled shIL6-
expressing cells exhibited comparable proliferative ability to shGFP-
Kaede cells. Restoration of the proliferation of Kaede-labeled cells was
not observed in the shIL6 + shIL6-Kaede. These observations indicate
that IL-6-producing cells (i.e., the shGFP cells here) can rescue the
proliferation of shIL6-expressing cells.
To analyze whether secreted IL-6 maintains cell proliferation in
basal-like breast cancer, recombinant human IL-6was added to cultures
of cells expressing shIL6. Results showed that IL-6-treatment signiﬁ-
cantly increased cell proliferation compared with PBS treatment
(Fig. 7D,E). This result indicates that restoration of the proliferation of
shIL6-expressing cells in the co-culture experiments is due to cancer-
secreted IL-6 rather than to cell-to-cell contact.
IL-6 signaling activates STAT3 by phosphorylating at tyrosine 705. To
analyze changes in STAT3 activity in shIL6-cells, we used an antibody
targeting phosphorylated tyrosine 705 on STAT3 (pSTAT3) in immuno-
cytochemistry. Strong pSTAT3 signals were detected in cells expressing
shGFP (Fig. 8A), in comparison to the weak signals observed in shIL6-
cells (Fig. 8B), indicating that STAT3 activation decreased in response
to attenuated of IL-6 signaling. Double-staining was performed in
co-culture experiments with anti-FLAG antibodies to distinguish
Kaede-labeled shIL6-expressing cells from the unlabeled co-culture
partners. The reduced STAT3 activation in shIL6-Kaede cells was
rescued when the cells were co-cultured with the shGFP- (Fig. 8C,
yellow arrowhead), but not with shIL6-cells (Fig. 8D). The amount of
STAT3 seemed to remain unchanged between shGFP- and shIL6-A) To analyze proliferation in co-culture experiments, Kaede-expressing cells were mixed
beled cells was analyzed by measuring the red intensity. Images are representative of the
-expressing Hs578T (B, n = 4) and MDA-MB-231 cells (C, n = 4) are shown. Cells were
IL-6 administration on shIL6-expressing Hs578T cells (D, n= 4) and MDA-MB-231 cells
ental and control groups at each time point. n.s.: non-signiﬁcant change, *: P b 0.05,
Fig. 8. Rescue of STAT3 activation by co-culturing with IL-6-producing cells. (A,B) Immu-
nostaining for pSTAT3 in shGFP (A) and shIL6 cells (B) is shown. (C,D) STAT3 activation
attenuated by shIL6 was restored following co-culturing with shGFP-expressing cells
(C), but not with shIL6-expressing cells (D). The Kaede signal was detected by an anti-
FLAG antibody. Yellow arrowheads in C indicate pSTAT3-positive, shIL6-expressing,
Kaede-labeled cells. Bars indicate 100 μm.
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secreted IL-6 induces STAT3 activation in other cells.
Taken together, the results of the co-culture experiments and
recombinant IL-6 treatments indicate that IL-6 can act in a paracrine
manner in basal-like breast cancer cells, consistent with previous
studies [15,30]. IL-6-producing cancers secrete IL-6. Speciﬁcally, IL-6
secreted by IL-6-producing cancers activates STAT3 to stimulate cell
proliferation in basal-like breast cancer cells, but not in luminal breast
cancer.
4. Discussion
4.1. Visualization and quantiﬁcation of cell proliferation
Novel techniques exploring the cellular activity, such as prolifera-
tion, contribute to the development of cell biology. In this study, we
established a new proliferation assay system, the OPA system. We
used a photoconvertible ﬂuorescent protein, Kaede, and determined
that measuring the reduction in Kaede-red ﬂuorescent intensity
shows the degree of proliferation in living cells. The OPA system is use-
ful for time-course analyses, as well as for the analyses of the prolifera-
tive ability of a speciﬁc group of cells in co-culture experiments.
Currently, various methods have been established for the visualiza-
tion of cell proliferation. FUCCI is a ﬂuorescent protein-based cell cycle
imaging system [31]. FUCCI allows us to monitor cell cycle progression
by ﬂuorescence. In the FUCCI system, red and green ﬂuorescence
indicate that cells are in the G1 phase and the S toMphase, respectively.
Anillin is one of the contractile ring proteins, and is involved in cytoplas-
mic division. Localization changes of EGFP–anillin fusions indicate
progression through the M phase [32]. Rayleigh/Raman spectroscopy
provides information about changes in cellular components, such as
DNA and protein. Researchers using this spectroscope have reported
observations of cell cycle progression at the single-cell level [33].
These methods visualize the dynamics of cell cycle progression via
time-lapse imaging, and identify proliferating cells at a speciﬁc time
point by taking a picture. Differing from these techniques, in the OPAsystem, the degree of reduction in red ﬂuorescence indicates whether
cell proliferation has occurred during a particular experimental period.
The OPA system can trace the proliferation and it is easy to compare
the proliferative abilities of the control and experimental groups.
Systems similar to the OPA system have been proposed. A previous
study has documented reduction in Kaede-red intensity following cell
division [34]. However, the authors concluded that it was difﬁcult for
their system to analyze cell proliferation via ﬂow cytometry. Corrobo-
rating this previous study, we also found that Kaede ﬂuorescence data
acquired using a ﬂow cytometer were not clear, and it was difﬁcult to
identify the signatures of proliferating cells. Instead of using ﬂow
cytometry, we therefore measured the red intensity using microscope
images, and then calculated the relative values and analyzed the
changes in the mean relative red intensity. The Kaede protein has
been used to analyze the proliferation in zebraﬁsh ﬁn regeneration
[35], although the proliferation was not quantiﬁed. Pulse labeling with
histone 2B-GFP has been used to identify low or non-proliferating
cells [36]. A commercially available cell labeling dye, carboxyﬂuorescein
succinimidyl ester (CFSE), can also be used to quantify cell proliferation.
The ﬂuorescence of CFSE is reduced after every cell division and the
degree of reduction in CFSE signal reﬂects the level of cell proliferation.
However, due to the requirements of the CFSE detection procedure,
the CFSE method is not suited for time course analyses. By using the
OPA system, we succeeded in quantitatively analyzing changes in cell
proliferation over time in response to pharmacological treatments and
genetic manipulation (Fig. 4). The OPA systemwill be valuable in future
studies that require observation of cell proliferation over a speciﬁc time
course.
4.2. The function of IL-6 in breast cancer cell proliferation
IL-6 is one of many extracellular signaling molecules, although
its impact on cell proliferation is controversial in the context of breast
cancer [17]. Inhibition of cell proliferation by adding recombinant IL-6
has been reported for luminal breast cancer cells, such as in T-47D,
ZR-75-1, and MCF-7 cells [37–40], and in basal-like breast cancer cells,
such as MDA-MB-231 cells [40]. There are other studies comparing
the effect of IL-6 on proliferation between luminal and basal-like breast
cancer subtypes [41–43]. These studies have shown that luminal cancer
ismore sensitive to proliferative inhibition by IL-6 than basal-like breast
cancer. Studies that treated luminal breast cancer cells, i.e., MDA-MB-
415 [44] and MCF-7 cells [45], with IL-6 showed no effect on prolifera-
tion.MCF10A is a normalmammary epithelial cell line. The proliferation
of transformed MCF10A cells is not affected by the expression of IL6
shRNA [46].
In contrast to these studies, positive effects of IL-6 have also been
reported. Growth of MCF10A cells is enhanced by the addition of
supernatants from MDA-MB-231 cultures, with an increase in STAT3
phosphorylation [14]. Administration of IL-6 also enhances the prolifer-
ation ofMCF-7 cells aswell as the proliferation of a HER2-positive breast
cancer cell line, BT-474 [30,47]. In the study on MCF-7 cells, no effect
was observed following administration of IL-6, although proliferation
was reduced by IL-6 depletion with antibody and with antisense oligo-
nucleotides. A reduction in proliferation by IL-6 depletion is rescued by
the administration of recombinant IL-6 [48]. Recombinant IL-6 increases
the proliferation of the basal-like breast cancer cell Hs578T that had IL-6
knocked down [15]. It is thus evident that the effect of IL-6 treatment
and IL-6 inhibition tend to vary between studies. These differences
might be caused by differences in culture conditions, such as the
medium used, culture scale, and cell density, and in assay methods.
In this study, we observed a reduction in proliferation after IL-6
knockdown in basal-like breast cancer cells, but not in luminal breast
cancer (Fig. 6), suggesting that the function of IL-6 on proliferation
differs among breast cancer subtypes. Reduction in proliferative ability
after IL-6 knockdown in basal-like breast cancer was not as severe
as observed after the BMI1 knockdown shown in Fig. 4I. Our IL-6
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that IL-6 signaling is involved in basal-like breast cancer proliferation,
but is not a major factor. Similar to previous studies [15,48], we
observed that the reduced proliferative ability of IL-6-knockdown cells
could be restored by co-culturing these with IL-6-producing cells, and
also by recombinant IL-6 treatment (Fig. 7). Our results indicate that
basal-like breast cancer secretes IL-6 to promote the proliferation of
other basal-like breast cancer cells. A previous study has shown that
high STAT3 activation is observed in cancer stem cell populations,
deﬁned as CD44+ CD24− cells [15]. Further study is required to
understand the function of cancer cell-secreted IL-6 in stemness, and
the OPA system may facilitate the study of the role and function of
IL-6 in cancer stem cell proliferation.
5. Conclusions
In this study, we visualized and quantiﬁed cell proliferation using
the OPA system. We showed that IL-6 signaling positively regulates
cell proliferation in basal-like breast cancer. Furthermore, we obtained
direct evidence of IL-6 exhibiting a paracrine effect. Our results indicate
that cancer cells can promote the proliferation of other cancer cells by
secreting signaling molecules.
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